Prognosis of PN3 Stage Gastric Cancer

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2009 Aug 27

PMID 19707504

Citations 7

Authors

Jung Ryun Ahn

Minkyu Jung

Chan Kim

Min Hee Hong

Hong Jae Chon

Hye Ryun Kim

Hei-Cheul Jeung

Woo Jin Hyung

Sung Sook Lee

Hyun Cheol Chung

Sung Hoon Noh

Sun Young Rha

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to determine the prognosis of pN3 stage gastric cancer patients after they have undergone curative resection, and we also wanted to identify the prognostic factors according to the clinico-pathologic features.

Materials And Methods: Between January 2000 and December 2004, we retrospectively reviewed the medical records of the patients with histologically confirmed pN3 stage gastric cancer. They underwent both gastrectomy and lymphadenectomy with a curative aim. We categorized the pN3 stage patients into 2 groups; one with pN3 only (pN3M0) and the other with pN3 combined with M1 stage (pN3M1) that included peritoneal seeding, hepatic metastasis or para-aortic LN metastasis.

Results: Out of 467 patients with stage IV gastric adenocarcinoma who received surgery, 260 patients underwent curative resection and they were pathologically staged as N3. Among these 260 patients, 78 patients were classified as the pN3/M1 stage. For all the patients, the median follow-up period was 19 months (range: 1~108 months) and the median overall survival time was 16.2 months (95% CI, 14.1~18.3%). The 5-year survival rate of the pN3/M0 group was significantly higher than that of the pN3/M1 group (12.6% vs. 2.6%, respectively, p<0.0001). The identified predictor for a worse prognosis was an advanced T4 stage (HR: 3.38, 95% CI, 1.4~8.3, p=0.008) for the pN3 patients.

Conclusion: The survival for the pN3 gastric cancer patients after curative gastrectomy was significantly longer in the pN3/M0 group as compared to that of the pN3/M1 group. An advanced T stage was a predictor for a poor prognosis for the pN3 patients. Therefore, diverse treatment strategies for these heterogeneous pN3 gastric cancer patients are needed for improving their survival.

Citing Articles

S100A10 Accelerates Aerobic Glycolysis and Malignant Growth by Activating mTOR-Signaling Pathway in Gastric Cancer.

Li Y, Li X, Li L, Zhou R, Sikong Y, Gu X Front Cell Dev Biol. 2020; 8:559486.

PMID: 33324631 PMC: 7726224. DOI: 10.3389/fcell.2020.559486.

Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer.

Gong Z, Zhang J, Guo W Cancer Med. 2020; 9(23):9052-9063.

PMID: 33030278 PMC: 7724479. DOI: 10.1002/cam4.3505.

Is it worthy of adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for distal gastric cancers with No. 6 lymph node metastasis?.

Zhang J, Zou S, Luo R, Zhu Z, Wang Z, Xu H Clin Transl Oncol. 2019; 21(12):1699-1706.

PMID: 30977046 DOI: 10.1007/s12094-019-02103-0.

Prognostic Discrepancy of the 6th and 7th UICC N Classification for Lymph Node Staging in Gastric Cancer Patients after Curative Resection.

Oh S, Suh B, Park J, Oh S, Yu H Case Rep Oncol. 2017; 10(1):57-65.

PMID: 28203165 PMC: 5301159. DOI: 10.1159/000455189.

Gastric biomarkers: a global review.

Baniak N, Senger J, Ahmed S, Kanthan S, Kanthan R World J Surg Oncol. 2016; 14(1):212.

PMID: 27514667 PMC: 4982433. DOI: 10.1186/s12957-016-0969-3.

References

Catalano V, Labianca R, Beretta G, Gatta G, De Braud F, Van Cutsem E . Gastric cancer. Crit Rev Oncol Hematol. 2009; 71(2):127-64. DOI: 10.1016/j.critrevonc.2009.01.004. View

Lin S, Tong H, You T, Yu Y, Wu W, Chen C . Palliative gastrectomy and chemotherapy for stage IV gastric cancer. J Cancer Res Clin Oncol. 2007; 134(2):187-92. DOI: 10.1007/s00432-007-0268-z. View

Li C, Yan M, Chen J, Xiang M, Zhu Z, Lin Y . Prognostic influence of sub-stages according to pTNM categories in patients with stage IV gastric cancer. J Surg Oncol. 2009; 99(6):324-8. DOI: 10.1002/jso.21242. View

Kranenbarg E, Hermans J, van Krieken J, van de Velde C . Evaluation of the 5th edition of the TNM classification for gastric cancer: improved prognostic value. Br J Cancer. 2001; 84(1):64-71. PMC: 2363617. DOI: 10.1054/bjoc.2000.1548. View

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

An J, Ha T, Noh J, Sohn T, Kim S . Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM. Arch Surg. 2009; 144(1):38-45. DOI: 10.1001/archsurg.2008.502. View

Medina-Franco H, Contreras-Saldivar A, Ramos-De la Medina A, Palacios-Sanchez P, Cortes-Gonzalez R, Ugarte J . Surgery for stage IV gastric cancer. Am J Surg. 2004; 187(4):543-6. DOI: 10.1016/j.amjsurg.2003.12.045. View

Lim S, Muhs B, Marcus S, Newman E, Berman R, Hiotis S . Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups?. J Surg Oncol. 2007; 95(2):118-22. DOI: 10.1002/jso.20328. View

10.

Hartgrink H, Putter H, Kranenbarg E, Bonenkamp J, van de Velde C . Value of palliative resection in gastric cancer. Br J Surg. 2002; 89(11):1438-43. DOI: 10.1046/j.1365-2168.2002.02220.x. View

11.

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357(18):1810-20. DOI: 10.1056/NEJMoa072252. View

12.

Yoo C, Noh S, Kim Y, Min J . Comparison of prognostic significance of nodal staging between old (4th edition) and new (5th edition) UICC TNM classification for gastric carcinoma. International Union Against Cancer. World J Surg. 1999; 23(5):492-7; discussion 497-8. DOI: 10.1007/pl00012337. View

13.

Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View

14.

Takeno S, Noguchi T, Kikuchi R, Sato T, Uchida Y, Yokoyama S . Analysis of the survival period in resectable stage IV gastric cancer. Ann Surg Oncol. 2001; 8(3):215-21. DOI: 10.1007/s10434-001-0215-1. View

15.

Kunisaki C, Makino H, Takagawa R, Oshima T, Nagano Y, Kosaka T . Tumor diameter as a prognostic factor in patients with gastric cancer. Ann Surg Oncol. 2008; 15(7):1959-67. DOI: 10.1245/s10434-008-9884-3. View

16.

Yook J, Oh S, Kim B . Clinicopathological analysis of Borrmann type IV gastric cancer. Cancer Res Treat. 2009; 37(2):87-91. PMC: 2785394. DOI: 10.4143/crt.2005.37.2.87. View

17.

Park J, Park S, Mok Y, Kim C . pN3M0 gastric cancer: the category that allows the sub-classification of stage-IV gastric cancer (IVa and IVb). Ann Surg Oncol. 2007; 14(9):2535-42. DOI: 10.1245/s10434-007-9445-1. View

18.

An J, Kang T, Choi M, Noh J, Sohn T, Kim S . Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J Gastrointest Surg. 2008; 12(8):1364-9. DOI: 10.1007/s11605-008-0516-9. View

19.

Japanese Gastric Cancer Association . Japanese Classification of Gastric Carcinoma - 2nd English Edition -. Gastric Cancer. 2002; 1(1):10-24. DOI: 10.1007/s101209800016. View